Introduction {#Sec1}
============

On January 24, 2020, a new virus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been identified, quickly gaining worldwide attention \[[@CR21]\]. More than one third of patients with SARS-CoV-2 develop neurological manifestations \[[@CR10]\]. Similarly to other Coronavirus, SARS-CoV-2 can attack the olfactory bulb and then affect the central nervous system (CNS) through the olfactory tract in the early stages of infection \[[@CR5]\]. Neurological impairment and demyelinating reaction appear as complications in case of severe Coronavirus Disease 2019 (COVID-19) \[[@CR10]\]. We described the case of a COVID-19 patient with newly diagnosed demyelinating lesions.

Case report {#Sec2}
===========

A 54 years old women, with a past medical history of anterior communicating artery (AComA) aneurysm treated surgically 20 years before, was found unconscious at home. When the rescue arrived, she regained consciousness and became unrest. At the emergency department, a brief neurological examination revealed a GCS of 12 (E3 M6 V3), without focal sensorimotor deficits. No signs of both tongue biting and incontinence were reported by the familiars. Anosmia and ageusia were referred by several days. Head CT scan was normal (Fig. [1](#Fig1){ref-type="fig"}). Chest X-ray (Fig. [2](#Fig2){ref-type="fig"}) revealed an interstitial pneumonia (IP), and real-time polymerase chain reaction (RT-PCR) for SARS-CoV-2 was positive.Fig. 1Head-CT scan: right frontotemporal craniotomy (previous AComA aneurysm surgery). No evidence of acute injuriesFig. 2Chest X-ray: typical COVID-19 interstitial pneumonia

The patient was admitted to our Neurosurgical Unit and complete blood tests showed moderate lymphocytopenia with mild elevation of inflammatory indices (WBC 8.81/mm^3^, Ly 0.3/mm^3^, CRP 41.3 mg/L, Fibrinogen 520 mg/dL). Both blood and urinary cultures were negative. Antiretroviral and hydroxychloroquine were started. No abnormalities at arterial blood gas (ABG) analysis were detected (pO2 89, pCO2 41, pH 7.43).

After few hours, the patient clinically deteriorated. Body temperature was normal, and no electrolyte disorders were found. ABG revealed a severe normocapnic hypoxia. Therefore, she was intubated. Subsequent head CT scan was unchanged. Electroencephalography showed two seizures starting from right frontotemporal region and diffusing in homologous contralateral hemisphere. Antiepileptic therapy with lacosamide, levetiracetam, and phenytoin was started with seizures control.

Brain MRI revealed alterations of the periventricular white matter, hyperintense in T2WI, without restriction of diffusion nor contrast enhancement (Fig. [3a--f](#Fig3){ref-type="fig"}). Similar lesions were found at the bulbo-medullary junction and in both the cervical and dorsal spinal cord (Fig. [3g](#Fig3){ref-type="fig"}). Chemical-physical cerebrospinal fluid (CSF) examination was normal, and further analysis ruled out multiple sclerosis. The CSF RT-PCR for neurotropic viruses, including SARS-CoV-2, was negative.Fig. 3Head-MRI Flair axial view (a), (b), (c), and sagittal view (d), (e), (f): numerous periventricular white matter alterations, confluent with each other and compatible with demyelinating lesions, adjacent to the temporal, frontal and occipital horns and to the trigones, hyperintense in T2, without restriction of diffusion and without contrast enhancement; cervical and dorsal MRI T2WI sagittal view (g): numerous focal hyperintense intramedullary signal alterations in T2 and without contrast enhancement, located at the bulb-medullary junction, at C2 and from C3 to Th 6

High-dose steroid treatment (dexamethasone 20 mg/die for 10 days and 10 mg/die for 10 days) allowed a progressive recovery of the pulmonary impairment. The patient was tracheostomized on the 7th day. After 15 days, ventilator weaning was performed, and the patient was discharged from the intensive care unit (ICU) and addressed to our Neurosurgical Unit. The patient was transferred to rehabilitation without sensorimotor deficits after 12 days.

Discussion {#Sec3}
==========

The family of Coronaviruses shows a potential neurotropism that can induce neurological disorders like polyneuropathy, encephalopathy, demyelinating lesions, and ischemic stroke \[[@CR8], [@CR15]\]. The main clinical manifestations are headache, disturbance of consciousness, paralysis, paraesthesia, and seizures \[[@CR14]\]. The neurological complications could appear delayed to respiratory symptoms \[[@CR8]\].

SARS-CoV-2 shows a genetic similarity to SARS-CoV and MERS-CoV \[[@CR4], [@CR17]\] and presents an analogous neurotropism. Previous articles showed that a large number of patients report anosmia and dysgeusia. Moreover COVID-19 may lead to symptoms similar to intracranial infections \[[@CR2]\].

Our patient showed symptoms consistent with a neurological involvement consequent to SARS-CoV-2 infection. Anosmia and dysgeusia appeared early, while seizures occurred as COVID-19 complication. Moriguchi explains seizures as results of SARS-CoV-2 encephalitis \[[@CR12]\]. Otherwise, we observed demyelinating lesions related to the neurological impairment.

The presence of demyelination, as well as SARS-CoV virus particles and genome sequences, in the brain has been detected in autopsy studies \[[@CR6], [@CR19]\]. Our patient's brain and spine MRI showed new onset of multiple, non-enhancing demyelinating lesions. Previous cerebral MRI controls performed as follow-up after the AComA aneurysm surgery were normal. Multiple sclerosis (MS), viral encephalitis, and bacterial infections were excluded. Therefore, we speculated a pathogenesis SARS-CoV-2 related.

Neurotropism may occur via trans-lamina cribrosa that enables SARS-CoV-2 to reach the brain through the olfactory tract \[[@CR1]\]. The interaction between the spike protein S1 and the host ACE-2 receptor, expressed in the capillary endothelium, allows the virus to penetrate into the neuronal cells \[[@CR16]\]. The viral particles budding lead to the onset of symptoms such as anosmia and dysgeusia in the early phase of infection \[[@CR10]\].

The delayed CNS damage appears mediated by the immune system \[[@CR9]\]. As previously demonstrated, the pathogenesis of severe viral infections is closely linked to the development of virus induced systemic inflammatory response syndrome (SIRS) or SIRS-like immune disorders \[[@CR3]\]. For SARS-CoV-2 infection, the pro-inflammatory state induced by the cytokine storm, mainly sustained by IL1, IL-6, and TNF α, may be responsible of the activation of glial cells with subsequent demyelination \[[@CR11]\]. A possible alternative could be the production of antibodies against glial cells triggered by the virus, as a para-infective or post-infective phenomenon. Zhao described a case report of Guillan-Barrè syndrome during SARS-CoV-2 infection \[[@CR20]\]. Moreover, SARS-CoV-2 may play a role of infective trigger, similar to the one of Epstein Barr virus in MS.

In SARS-CoV-2 infection, neurological impairment was observed only in case of severe COVID-19 \[[@CR10]\]. As a matter of fact, our patient showed an IP that required ICU. Therefore, we supposed that a severe pneumonia with subsequent CNS hypoxia that leads to an increased anaerobic metabolism is required to trigger a neurological damage.

SARS-CoV-2 was not detected in the CSF probably because the neurological damage was sustained by a delayed immune response that occurred after the viremia. Moreover, as reported by different authors, CSF clearance, low sensibility of the method, and delayed sampling could explain this occurrence \[[@CR7], [@CR13], [@CR18]\].

Conclusion {#Sec4}
==========

Sudden neurological impairment with seizures in COVID-19 patients may be sustained by CNS involvement and demyelinating lesions. Early CSF collection is suggested. Prompt invasive treatment should be adopted to avoid hypoxic neurotoxicity and prevent CNS injuries.
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